Staphylococcus aureus Targets the Duffy Antigen Receptor for Chemokines (DARC) to Lyse Erythrocytes  by Spaan, András N. et al.
Short Article
Staphylococcus aureus Targets the Duffy Antigen
Receptor for Chemokines (DARC) to Lyse
ErythrocytesGraphical AbstractHighlightsd The S. aureus leukocidins HlgAB and LukED target DARC to
lyse erythrocytes
d HlgAB and LukED differentially interact with DARC
d DARC polymorphisms explain interindividual differences in
hemolysis susceptibility
d DARC targeting by HlgAB and LukED contributes to S. aureus
growthSpaan et al., 2015, Cell Host & Microbe 18, 363–370
September 9, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.chom.2015.08.001Authors
Andra´s N. Spaan, Tamara
Reyes-Robles, Ce´dric Badiou, ...,
Jos A.G. van Strijp, Thomas Henry,
Victor J. Torres
Correspondence
thomas.henry@inserm.fr (T.H.),
victor.torres@nyumc.org (V.J.T.)
In Brief
Several Staphylococcus aureus bi-
component leukocidins lyse
erythrocytes, which is thought to provide
iron for bacterial growth. Spaan and
Reyes-Robles et al. demonstrate that the
Duffy antigen receptor for chemokines
(DARC) is the erythroid receptor for
leukocidins and that targeting DARC
promotes S. aureus growth in a
hemoglobin acquisition-dependent
manner.
Cell Host & Microbe
Short ArticleStaphylococcus aureus Targets
the Duffy Antigen Receptor
for Chemokines (DARC) to Lyse Erythrocytes
Andra´s N. Spaan,1,2,3,9 Tamara Reyes-Robles,4,9 Ce´dric Badiou,1,2 Sylvie Cochet,5,6 Kristina M. Boguslawski,4
Pauline Yoong,4 Christopher J. Day,7 Carla J.C. de Haas,3 Kok P.M. van Kessel,3 Franc¸ois Vandenesch,1,2,8
Michael P. Jennings,7 Caroline Le Van Kim,5,6 Yves Colin,5,6 Jos A.G. van Strijp,3 Thomas Henry,1,2,10,*
and Victor J. Torres4,10,*
1CIRI, Inserm U1111, CNRS UMR 5308, Lyon, France
2Universite´ Claude Bernard Lyon-1, Ecole Normale Supe´rieure, 69007 Lyon, France
3Department of Medical Microbiology, University Medical Center Utrecht, 3584CX Utrecht, The Netherlands
4Department of Microbiology, New York University School of Medicine, NY 10016, USA
5Inserm U1134, Paris, France; Universite´ Paris Diderot, Sorbonne Paris Cite´, UMR_S1134, Paris, France
6Institut National de la Transfusion Sanguine, F-75739 Paris, France; Laboratoire d’Excellence GR-Ex, 75238 Paris, France
7Institute for Glycomics, Griffith University, Gold Coast, Queensland 4222, Australia
8Hospices Civils de Lyon, 69007 Lyon, France
9Co-first Author
10Co-senior author
*Correspondence: thomas.henry@inserm.fr (T.H.), victor.torres@nyumc.org (V.J.T.)
http://dx.doi.org/10.1016/j.chom.2015.08.001SUMMARY
In order for Staphylococcus aureus to thrive inside
the mammalian host, the bacterium has to overcome
iron scarcity. S. aureus is thought to produce toxins
that lyse erythrocytes, releasing hemoglobin, the
most abundant iron source in mammals. Here we
identify the Duffy antigen receptor for chemokines
(DARC) as the receptor for the S. aureus hemolytic
leukocidins LukED and HlgAB. By assessing human
erythrocytes with DARC polymorphisms, we deter-
mined that HlgAB- and LukED-mediated lysis
directly relates to DARC expression. DARC is
required for S. aureus-mediated lysis of human
erythrocytes, and DARC overexpression is sufficient
to render cells susceptible to toxin-mediated lysis.
HlgA and LukE bind directly to DARC through
different regions, and by targeting DARC, HlgAB
and LukED support S. aureus growth in a hemoglo-
bin-acquisition-dependent manner. These findings
elucidate how S. aureus targets and lyses erythro-
cytes to release one of the scarcest nutrients within
the mammalian host.
INTRODUCTION
Staphylococcus aureus (S. aureus) is an important human path-
ogen that plagues patients in hospitals worldwide, especially
since the emergence of antibiotic resistance. S. aureus infec-
tions range from minor skin and soft tissue infections to more
invasive and life-threating infections like sepsis, endocarditis,
osteomyelitis, and pneumonia (Chambers and Deleo, 2009).Cell Host &The pathogenesis of this bacterium is multifactorial and is
exacerbated by the combination of resistance to many antibi-
otics and the production of an arsenal of virulence factors
(DeLeo et al., 2009).
To prevail in the harsh environments encountered in the
bloodstream and deeper body tissues of the human host,
pathogenic organisms must cope with the onslaught carried
by the host innate immune system (Spaan et al., 2013b).
S. aureus addresses this by producing a large number of im-
mune-modulatory factors, including potent pore-forming
toxins, that tamper with innate immunity (Spaan et al.,
2013b; Vandenesch et al., 2012). Among these toxins, a single
S. aureus clone associated with human infections can produce
up to five bi-component leukocidins: LukSF-PV (or PVL),
HlgAB and HlgCB (also known as gamma-toxins), LukED,
and LukAB (also known as LukGH) (Alonzo and Torres,
2014), which target and eliminate specific innate and adaptive
immune cell populations, contributing to S. aureus
pathobiology.
Invading pathogens also have to overcome the barrier posed
by nutrient limitation (Waldron and Robinson, 2009). As with
many pathogens (Schaible and Kaufmann, 2004), iron is
essential for proliferation and virulence of S. aureus (Cassat
and Skaar, 2013). In the host, however, free iron is scarce,
an innate immune defense strategy of the host known as
‘‘nutritional immunity’’ (Andrews et al., 2003; Schaible and
Kaufmann, 2004; Weinberg, 1975). The main reservoir of iron
in the host lies within erythrocytes, where iron is sequestered
and bound to heme within hemoglobin. Heme iron is
S. aureus’s preferred iron source during infection (Skaar
et al., 2004). Although hemoglobin usage by S. aureus has
been extensively investigated, little is known about the actual
release of hemoglobin from erythrocytes. While it is presumed
that S. aureus releases hemoglobin from erythrocytes by the
action of hemolytic toxins, experimental data supporting thisMicrobe 18, 363–370, September 9, 2015 ª2015 Elsevier Inc. 363
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Figure 1. Hemolytic Activity of HlgAB and
LukED Depends on DARC
(A) Susceptibility of human erythrocytes to
S. aureus b-barrel pore-forming toxins. The dashed
line indicates 50% hemolysis. n = 6 ± SEM.
(B) Levels of DARC and CD55 on erythrocytes of
donors with different Fy phenotypes. The dashed
line indicates the detection threshold. n = 2–7 ±
SEM.
(C) Susceptibility of human erythrocytes with
different Fy phenotypes to HlgAB. The dashed line
indicates 50% hemolysis. n = 2–7 ± SEM.
(D) Correlation of half-maximal effective concen-
trations (EC50) of HlgAB with the total number of
receptors expressed on the erythrocyte surface.
n = 2–7 ± SEM.
(E) Susceptibility of human erythrocytes with
different Fy phenotypes to LukED. The dashed line
indicates 50% hemolysis. n = 2–7 ± SEM.
(F) Correlation of half-maximal effective concen-
trations (EC50) of LukED with the total number of
receptors expressed on the erythrocyte surface.
For Fyb+weak/Fyb- donors, EC50 could not be
calculated. n = 2–7 ± SEM.notion are limited (Bernheimer et al., 1968; Skaar and Schnee-
wind, 2004).
Staphylococcal toxins with hemolytic activity include a-toxin,
b-hemolysin, and phenol-soluble modulins (PSMs). Although a
potent hemolysin on mouse, rabbit, and sheep erythrocytes,
a-toxin has limited hemolytic activity toward human erythro-
cytes (Hildebrand et al., 1991) due to the lack of its receptor,
ADAM10 (Wilke and Bubeck Wardenburg, 2010). b-hemolysin
(encoded by the hlb gene) is an enzyme with sphingomyelinase
activity. Erythrocyte lysis by b-hemolysin is observed only after
heat-cold shock incubation (Bernheimer et al., 1974), and in
90% of S. aureus isolates, the hlb gene is inactivated by inte-
gration of b-hemolysin-converting bacteriophages (van Wamel
et al., 2006). PSMs, including d-toxin, are small amphipathic
peptides that perforate lipid bilayer membranes in a receptor-
independent manner (Wang et al., 2007). Cytotoxic activity of
PSMs is neutralized by serum lipoproteins (Surewaard et al.,
2012). As such, the contribution of a-toxin, b-hemolysin, and
PSMs to the release of iron from human erythrocytes seems
unlikely.
The bi-component pore-forming leukocidins are considered
a pathogenic strategy to evade the cellular host immune
response (Alonzo and Torres, 2014; Spaan et al., 2013b). The
respective immune cell receptor counterparts of these leukoci-
dins have been identified (Alonzo et al., 2013; DuMont et al.,
2013; Reyes-Robles et al., 2013; Spaan et al., 2013a, 2014).
Interestingly, several of the leukocidins also exhibit hemolytic
activity (Vandenesch et al., 2012). Despite this, the hemolytic364 Cell Host & Microbe 18, 363–370, September 9, 2015 ª2015 Elsevier Inc.activity of the toxins remains unexplained
by the reported leukocyte receptors.
Here, we identify the Duffy antigen
receptor for chemokines (DARC) as the
erythroid receptor for both HlgAB and
LukED, the main hemolytic leukocidins
in S. aureus. Using DARC-positiveand -negative erythrocytes, we show that hemolysis induced
by S. aureus is strictly mediated by DARC and these leukocidins
and that leukocidin-dependent hemolysis favors S. aureus
growth.
RESULTS
Hemolytic Activity of HlgAB and LukED Depends
on Erythroid Expression of DARC
Of the b-barrel pore-forming toxins produced by S. aureus,
HlgAB and LukED are the most potent hemolytic leukocidins
against human erythrocytes (Figure 1A). In contrast, HlgCB and
a-toxin induce only limited hemolysis, while PVL and LukAB
are inactive toward human erythrocytes (Figure 1A). The diver-
gent activity of HlgAB and HlgCB, which share HlgB, indicates
that HlgA drives erythroid specificity. The restricted hemolytic
activity of the different but closely related bi-component toxins
suggests targeting of specific cellular receptors.
While attempting to elucidate the molecular mechanisms of
hemolytic activity induced by these toxins, we observed differen-
tial susceptibility of human donors to the toxins, which was remi-
niscent of the susceptibility of erythrocytes to the malarial para-
sites Plasmodium vivax and Plasmodium knowlesi, which target
DARC for entry into erythrocytes (Miller et al., 1976; Miller et al.,
1975). P. vivax uses its surface molecule P. vivax Duffy Binding
Protein (PvDBP) to dock to the receptor (Choe et al., 2005; Tour-
namille et al., 2005). DARC is an atypical chemokine receptor
and the antigen of the Duffy (Fy) blood group system (Tournamille
AB
C
D
Figure 2. HlgAB and LukED Directly Target DARC
(A) Apparent dissociation constants (KD) of HlgA, HlgC, and LukE for purified
DARC as determined by SPR.
(B) Pore formation following HlgAB or LukED treatment in HEK293T cells
transfected with plasmids encoding DARC Fya, DARC Fyb, or CXCR1. The
dashed line indicates 50% pore formation. n = 3–5 ± SEM.
(C) Hemolytic activity of HlgAB and LukED on human erythrocytes incubated in
unbuffered or buffered media. The dashed line indicates 50% hemolysis. Bars
indicate SEM, with n = 3 ± SEM.
(D) Hemolytic activity of HlgAB and LukED on human erythrocytes under
different pH conditions. The dashed line indicates 50% hemolysis. Bars indi-
cate SEM, with n = 6 ± SEM.
See also Figures S1 and S2.et al., 1995, 1998; Wasniowska and Hadley, 1994). This system
discriminates two antigens (Fya and Fyb), based on a codon 42
polymorphism encoding a glycine in approximately half of hu-
man alleles (FY*A) and an aspartic acid in the other half (FY*B)
(Iwamoto et al., 1995). A substantial part of the human population
carries a homozygous mutation (FY*AES or FY*BES alleles for
erythrocyte silent) in the erythroid-specific promoter of the FY
gene, resulting in a lack of expression of the receptor on erythro-
cytes (Fya-/b- phenotype) but not in non-erythroid tissues (Tour-
namille et al., 1995; Zimmerman et al., 1999). This mutation is
highly prevalent in individuals of African descent (Tournamille
et al., 1995), and lack of erythroid DARC has been suggestedCell Host &to be an evolutionary adaptation to resist malaria in endemic
areas (Miller et al., 1976; Miller et al., 1975). Other, yet rare, mu-
tations result in low-level expression of DARC (allele FY*X result-
ing in Fyb+weak phenotype) (Tournamille et al., 1998).
To directly investigate if hemolysis by HlgAB and LukED is
mediated by DARC, we took advantage of erythrocyte samples
from genotyped individuals from the French National Blood
Transfusion Institute (INTS). In addition to genotyping, we eval-
uated DARC expression on erythrocyte surfaces (Figure 1B).
Indeed, DARC-negative erythrocytes (phenotype Fya/b
with genotype FY*BES/FY*BES) were fully resistant to HlgAB
and LukED (Figures 1C and 1E). Compared to individuals
expressing normal levels of DARC (phenotypes Fya+/b+,
Fya+/b+weak, Fya+/a+, and Fyb+/b+ with respective genotypes
FY*A/FY*B, FY*A/FY*X, FY*A/FY*A, and FY*B/FY*B), individuals
expressing intermediate (phenotype Fyb+weak/b+weak with
genotype FY*X/*X) or very low levels of DARC (phenotype
Fyb/b+weak with genotype FY*BES/FY*X) (Figure 1B) showed
intermediate susceptibility to both HlgAB and LukED (Figures
1C and 1E). Half-maximal effective concentration (EC50) of
the toxins directly correlated with the total number of receptors
on the erythrocyte surface (Figures 1D and 1F). The difference
in susceptibility to HlgAB and LukED between donors was
specifically related to erythroid expression levels of DARC,
as levels of CD55 (also known as DAF) were equal in all
donors (Figure 1B). Taken together, these data demonstrate
that the hemolytic activity of HlgAB and LukED is dependent
on DARC.
DARC Is the Receptor for HlgAB and LukED
on Erythrocytes
To determine if HlgAB and LukED directly bind DARC, surface
plasmon resonance (SPR) was performed using purified toxins
and receptor. HlgA and LukE bound DARC with a KD of
29.2 nM and 56.4 nM, respectively (Figure 2A). Consistent with
the limited hemolytic activity of HlgCB, the KD of HlgC for
DARC was 229.0 nM (Figure 2A). The KD value of HlgA for
DARC is approximately 6-fold higher compared to CXCR1,
which serves as a neutrophil receptor for HlgA (Spaan et al.,
2014). To investigate if DARC was sufficient to render host cells
susceptible to HlgAB and LukED, human embryonic kidney
(HEK293T) cells, which are resistant to both HlgAB and LukED
(Figure 2B), were transfected with DARC-Fya- or DARC-Fyb-en-
coding plasmids (Figure S1). Consistent with the obtained affin-
ities, at least a 10-fold higher EC50 was observed for both HlgAB
and LukED for DARC when compared to CXCR1 (Figure 2B).
DARC-Fya and -Fyb conferred equal susceptibility to these
toxins (Figure 2B).
Several of the S. aureus leukocidins exhibit species specificity,
which render them highly active against human cells, but notmu-
rine cells (DuMont and Torres, 2014). Thus, we also evaluated if
HlgAB and LukED can target murine DARC, which shares amino
acid sequence homology of approximately 63% with human
DARC (Luo et al., 1997). HEK293T cells were transfected with
plasmids encoding either murine or human DARC, and the sus-
ceptibility to the toxins was evaluated. In contrast to human
DARC, we observed that cells transfected with murine DARC
were more susceptible to LukED than to HlgAB (Figures S2A
and S2B). Consistent with the transfection data, primary murineMicrobe 18, 363–370, September 9, 2015 ª2015 Elsevier Inc. 365
erythrocytes were susceptible to both HlgAB and LukED
(Figure S2B).
It has been hypothesized that during skin infections and ab-
scess formation, ischemia and necrosis cause a local acidifica-
tion of the infected tissue, which leads to the conversion of ferric
ions into ferrous iron, the preferred iron source for S. aureus
(Skaar et al., 2004; Skaar and Schneewind, 2004). We observed
that the hemolytic activity of both HlgAB and LukED was
enhanced in saline (unbuffered) compared to buffer (Figure 2C).
Similar results were observed with murine erythrocytes (Fig-
ure S2C). Additional studies showed increased hemolytic activity
in low pH conditions (Figure 2D). Collectively, these data indicate
that DARC is sufficient to render mammalian cells susceptible to
HlgAB and LukED and that the hemolytic activity of these toxins
is likely to be influenced by the local environment of infected
tissues.
HlgAB and LukED Target Different DARC Regions
for Cell Killing
To tease out the interaction of HlgAB and LukED with DARC, we
screened HEK293T cells transfected with a collection of plas-
mids encoding DARC mutants (Tournamille et al., 2003). All re-
ceptors were expressed at similar levels on the cell surface of
transfected cells (Figure S1). Mutation of N-terminal glycosyla-
tion sites (N16A, N27A, or N33A) resulted in moderately reduced
susceptibility of cells toward HlgAB or LukED (Figures 3A and
3B). Mutation of the second N-terminal tyrosine (Y41A) but not
the first (Y30A) resulted in resistance to both HlgAB and LukED
(Figures 3A and 3B), which is similar to what has been observed
for PvDBP (Choe et al., 2005; Tournamille et al., 2005). Mutation
of a proline in close proximity to the first transmembrane region
of the receptor (P50A) reduced susceptibility to both toxins (Fig-
ures 3A and 3B). While mutation of two adjacent aspartic acid
residues (D58A+D59A) resulted in a partial resistance of cells
to HlgAB, mutation of the same residues enhanced susceptibility
to LukED (Figures 3A and 3B). Surprisingly, a disulfide bond-dis-
ruptingmutation (C51S) strongly affected susceptibility to LukED
but not to HlgAB (Figures 3A and 3B). Lastly, mutations in the
three extracellular loops (ECLs) differentially affected suscepti-
bility to HlgAB and LukED. Mutation of a glutamic acid in ECL2
(E202A) slightly enhanced susceptibility of cells to HlgAB but
reduced cytotoxicity of LukED. The inverse effect was observed
with aspartic acid in ECL3 (D283A) (Figures 3A and 3B).
Next, we tested if DARC competition with monoclonal anti-
bodies, chemokines, or PvDBP could interfere with hemolytic
activity. Pre-treatment of erythrocytes with the DARC ligand
CXCL8 (or IL-8) modestly shifted the EC50 for HlgAB (1.14 to
8.58 nM), while it completely antagonized hemolysis induced
by LukED irrespective of buffer conditions (Figures 3C and
S3A). In contrast to CXCL8, a commercially availablemonoclonal
against DARC (Fya) did not confer protection to HlgAB or LukED
(Figure S3B), nor did high concentrations of a nanobody target-
ing the DARC Fy6-epitope. Similarly, PvDBP did not antagonize
cytotoxicity of HlgAB, while it minimally protected against LukED
(Figure S3B).
To directly evaluate if CXCL8 inhibits LukED hemolytic activity
by blocking toxin-receptor interaction, we determined the effect
of CXCL8 on the formation of LukE-DARC and HlgA-DARC com-
plexes using SPR. CXCL8 did not affect HlgA binding to DARC366 Cell Host & Microbe 18, 363–370, September 9, 2015 ª2015 Els(Figure 3D). In contrast, CXCL8 significantly inhibited LukE bind-
ing to DARC when the chemokine was present at 4-fold (1:0.25)
or greater (1:0.125 and 1:0.0625) concentration than LukE (Fig-
ure 3D). Together, these data demonstrate that DARC targeting
by these toxins is dictated by different domains of the receptor.
S. aureus Lyses Erythrocytes in a Leukocidin- and
DARC-Dependent Manner
S. aureus presumably releases iron from erythrocytes by
secreting various hemolytic toxins, promoting the bacterium’s
survival in the host (Bernheimer et al., 1968; Skaar and Schnee-
wind, 2004; Torres et al., 2010). To address whether S. aureus ly-
ses erythrocytes in a DARC-dependent manner, the CA-MRSA
USA300 clone LACwas grown in the presence of DARC-positive
or -negative erythrocytes and hemolysis was measured over
time. We observed that S. aureus induced hemolysis of erythro-
cytes in a time-, bacterial-density-, and DARC-dependent
manner (Figures 4A and S4).
We next defined the contribution of HlgAB and LukED to
S. aureus-mediated lysis of DARC-positive erythrocytes. Growth
of isogenic strains revealed that HlgAB is sufficient for the
observed erythrocyte lysis in this ex vivo experiment (Figure 4B),
and this was recapitulated with different S. aureus strains (Fig-
ure S4B). Notably, the lack of a LukED contribution is not surpris-
ing due to low production of this toxin in vitro (Alonzo et al., 2012;
Gravet et al., 1998).
To directly evaluate if LukED and HlgAB promote bacterial
replication as a result of erythrocyte lysis, S. aureus was grown
in iron-starved medium supplemented with cell-free extracts of
erythrocytes treated with saline, LukED, or HlgAB. We observed
that HlgAB and LukED were each capable of promoting
S. aureus growth (Figure 4C). To determine if this growth was
dependent of hemoglobin acquisition, we used an isogenic
strain lacking the S. aureus hemoglobin receptors IsdB and
IsdH (DisdBH) (Pishchany et al., 2014; Torres et al., 2006). In
contrast to wild-type (WT) S. aureus, the DisdBH strain was
significantly growth impaired in medium supplemented with
cell-free extracts from toxin-treated erythrocytes (Figure 4C).
To elucidate the potential role of toxin-mediated erythrocyte
targeting in vivo, bacterial burden of mice infected systemically
withS. aureusWTor isogenicmutants lacking hlgACB and lukED
(Dhlg DlukED), the gene encoding for a-toxin (hla; Dhla), or isdBH
(DisdBH) (Figure S4C) were evaluated. Inactivation of lukED and
hlgACB phenocopied the deletion of the hemoglobin receptors,
resulting in a 3-log and 4-log reduction in bacterial burden,
respectively (Figure 4D). The bacterial burden reduction
observed with the Dhlg DlukED strain was specific, with no sig-
nificant difference between the bacterial burden of WT and
Dhla-infected mice, even though a-toxin exhibits hemolytic ac-
tivity in vitro toward murine erythrocytes (Figure S2C). Alto-
gether, these data suggest that S. aureus targets DARC to lyse
erythrocytes in a HlgAB- and LukED-dependent manner to
release hemoglobin, promoting bacterial replication.
DISCUSSION
It is presumed that S. aureus releases hemoglobin from erythro-
cytes by secreting hemolytic toxins. Strikingly, however, the
contribution of toxins to hemolysis-mediated bacterial growthevier Inc.
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Figure 3. HlgAB and LukED Target Different DARC Regions for Cell Killing
(A) Pore formation following HlgAB treatment (70 nM) in HEK293T cells transfected with plasmids encoding DARC Fya, DARC Fyb, or DARC alanine substitution
mutants. The dashed line indicates 50% pore formation. nR 18 ± SEM. Statistical significance is displayed as ns (not significant), *p < 0.05, **p < 0.01, and ***p <
0.005 using one-way ANOVA with Bonferroni post hoc test correction for multiple comparisons.
(B) Pore formation following LukED treatment (70 nM) in HEK293T cells transfected with plasmids encoding DARC Fya, DARC Fyb, or DARC alanine substitution
mutants. The dashed line indicates 50% pore formation. nR 18 ± SEM. Statistical significance is displayed as ns (not significant), *p < 0.05, **p < 0.01, and ***p <
0.005 using one-way ANOVA with Bonferroni post hoc test correction for multiple comparisons.
(C) Effect of pretreatment with CXCL8 (10 mg/ml) during hemolysis induced by HlgAB and LukED. n = 3 ± SEM.
(D) Competition between CXCL8 and toxin subunits at varying molar ratios using SPR. n = 3 ± SEM. *Indicates significant difference to non-CXCL8-treated
response units (p < 0.01) using t test.
See also Figure S3.has never been proven empirically. By identifying DARC as the
erythroid receptor for HlgAB and LukED, we show that these
staphylococcal bi-component toxins play a central role in human
erythrocyte lysis.
Our data show that the hemolytic activity of HlgAB and LukED
is in the nanomolar range and is exclusively driven by DARC
expression. The affinity of the binding components HlgA and
LukE for DARC is lower than their myeloid receptors, CXCR1
and CXCR2 (Reyes-Robles et al., 2013; Spaan et al., 2014).Cell Host &High expression levels of DARC and possibly lack of cellular
membrane repair mechanisms make erythrocytes highly sus-
ceptible to the toxins. Consistent with this, our data suggest
that the actual number of receptors on the cell surface dictates
susceptibility to these hemolytic toxins. Using alanine substitu-
tion mutants, we identified a tyrosine in the N terminus of
DARC that is essential for the interaction with both HlgAB and
LukED and has been described as sulfated (Choe et al., 2005).
For PVL, sulfation of tyrosines in the N-terminal C5aR is criticalMicrobe 18, 363–370, September 9, 2015 ª2015 Elsevier Inc. 367
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Figure 4. S. aureus Lyses Erythrocytes in a
HlgAB-, LukED-, and DARC-Dependent
Manner to Release Iron and Promote Growth
(A) S. aureusUSA300 LAC grown in the presence of
erythrocytes from donors with or without erythroid
expression of DARC and hemolysis measured.
Curves depict a representative sample.
(B) Hemolysis induced during overnight growth of
S. aureus strain USA300 LAC and its hlgA mutant
(hlgA::bursa) strain (infectious dose set at 1 3 106
CFU per sample). n = 3 ± SEM.
(C) Growth after 20 hr of S. aureus strains Newman
WT or isogenic DisdBH as a result of erythrocyte
lysis by LukED and HlgAB in iron-restricted me-
dium. n = 9 ± SEM. Statistical significance is dis-
played as ns (not significant), *p < 0.05, **p < 0.01,
and ****p < 0.0001 using one-way ANOVA with
Tukey’s post hoc test correction for multiple com-
parisons. Bacterial growth was measured at
OD600 nm.
(D) Swiss-Webster female mice (n = 10 mice per
group) infected systemicallywithS. aureusNewman
isogenicstrains:WT,DhlgDlukED,Dhla, andDisdBH
(1 3 107 colony forming units, CFU). 96 hr post
infection, mice were sacrificed and bacterial burden
in the liver determined. Lines represent median log
CFU. Statistical significance is displayed as ns (not
significant), *p < 0.05, **p < 0.01, and ****p < 0.0001
using one-way ANOVA with Tukey’s post hoc test
correction for multiple comparisons.
See also Figure S4.for initial binding of LukS-PV (Spaan et al., 2013a). Possibly,
sulfated N-terminal tyrosines define a conserved host interaction
site for the staphylococcal leukocidins. Otherwise, our data
show that HlgAB and LukED interact differentially with DARC.
An N-terminal cysteine (C51) identified as involved in the interac-
tion of DARCwith LukED is also involved in bindingCXCL8 (Tour-
namille et al., 2003), supporting the notion that this chemokine
directly blocks receptor binding by LukE.
The genes encoding HlgAB are present in over 99.5% of hu-
man S. aureus isolates (Prevost et al., 1995). Strictly following
clonal lineage, approximately 80% of S. aureus strains carry
the genes encoding LukED (McCarthy and Lindsay, 2013). The
S. aureus strains investigated in this study all contain the genes
encoding HlgAB and LukED, thus demonstrating that S. aureus-
mediated hemolysis requires DARC and these leukocidins.
S. aureus is remarkably well adapted to the human host, thus
multiple virulence factors of this bacterium are not compatible
with non-human species frequently used during in vivo studies.
One such factor is the staphylococcal hemoglobin receptor
IsdB, which exhibits low affinity for murine hemoglobin as
compared to human hemoglobin (Pishchany et al., 2010). Never-
theless, our in vivo studies revealed a remarkable similarity in the
phenotypes of isogenic mutants lacking either the hemoglobin
receptors or the hemolytic leukocidins, suggesting that these
toxins contribute to nutrient acquisition during infection. How-
ever, to unequivocally demonstrate that the attenuated pheno-
type exhibited by theDhlgDlukED strain is due to impaired eryth-
rocyte lysis, additional studies uncoupling the leukocidal and
hemolytic activities of HlgAB and LukED are required.
The current epidemic of CA-MRSA in the United States and
elsewhere disproportionally affects individuals of African368 Cell Host & Microbe 18, 363–370, September 9, 2015 ª2015 Elsdescent with severe and invasive infections (Fridkin et al.,
2005). Socio-economic factors and other underlying diseases
likely contribute to this predisposition, precluding epidemiolog-
ical assessment of the contribution of erythroid DARC
expression to S. aureus infection. However, the resistance of
DARC negative erythrocytes to the parasites P. vivax and
P. knowlesi, together with our findings, further support the
notion that this gene could undergo positive selection in
response to different diseases caused by important human
pathogens.
EXPERIMENTAL PROCEDURES
Ethics Statement
DARC blood samples were provided by the Centre National de Re´fe´rence sur
les Groupes Sanguins (CNRGS, Paris). Additional blood samples of consent-
ing, healthy volunteers were obtained in accordance with the Declaration of
Helsinki. Approval was obtained from the medical ethics committee of the
UMC Utrecht, The Netherlands. Blood was also obtained from de-identified,
consenting donors from the New York Blood Center.
All experiments involving animals were reviewed and approved by the Insti-
tutional Animal Care andUseCommittee of New York University and were per-
formed according to NIH guidelines, the Animal Welfare Act, and US Federal
law.
Hemolysis Assays with Recombinant Toxins
Erythrocytes were washed thrice in 0.9% saline, adjusted to 5 3 107 cells/ml,
and then intoxicated at a final of 2.5 3 107 cells/ml per reaction with purified
recombinant toxins for 30 min at 37C + 5% CO2 in a final volume of 160 ml.
Equimolar concentrations of 6xHis-tagged proteins were used. Samples
were centrifuged for 10 min at 1,780 3 g, 4C, and 100 ml of cell-free lysates
were used to measure absorbance (OD405 nm). Hemolysis is expressed as
the OD405 nm of cell-free lysates using an EnVision Plate Reader. The hemo-
lysis experiments with recombinant proteins were performed using bufferevier Inc.
containing 30mMTris with 100mMNaCl (pH 7.0) (buffered) or 0.9% saline (un-
buffered) as indicated.
S. aureus Burden In Vivo
To evaluate bacterial burden in vivo, 4-week-old Swiss-Webster mice (Harlan)
were anesthetized intraperitoneally with Avertin and infected retro-orbitally
with 100 ml of Newman isogenic strains WT, Dhlg DlukED, Dhla, and DisdBH
(1 3 107 CFU). 96 hr post-infection, mice were sacrificed, and the livers har-
vested, homogenized, and serially diluted.
Graphical and Statistical Analyses
Flow cytometric analyses were performed with FlowJo (Tree Star Software).
Statistical analyses were performed with Prism (GraphPad Software). Statisti-
cal significance was calculated using ANOVA and Student’s t tests with SEM
where appropriate.
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